Literature DB >> 6114930

Effect of inflammatory disease on plasma concentrations of three beta-adrenoceptor blocking agents.

R E Schneider, H Bishop, M J Kendall, C P Quarterman.   

Abstract

Plasma concentrations of three beta-adrenoceptor blocking agents, propranolol, oxprenolol, and metoprolol, have been measured over 24 h after a single oral dose in patients with active inflammatory disease, and in healthy subjects. After propranolol administration, peak plasma concentrations were approximately seven times higher in the patients; they remained significantly raised at all sampling times up to 10 h. With oxprenolol, peak plasma levels were about twice as high in the patients as in the healthy subjects and significantly raised on only two occasions. All plasma metoprolol values were within normal limits. These results did not run parallel with differences in metabolism between the three drugs, but did seem to relate to their degree of binding to plasma proteins (propranolol 93%, oxprenolol 80%, metoprolol 11%). Furthermore, it is known that propranolol binds to serum orosomucoid, an acute-phase reactant, which rises in inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114930

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  16 in total

1.  Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat.

Authors:  K M Kulmatycki; K Abouchehade; S Sattari; F Jamali
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Variability of beta-blocker pharmacokinetics in young volunteers.

Authors:  D B Jack; C P Quarterman; R Zaman; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

4.  Pharmacokinetics of pirprofen and its pyrrol metabolite in elderly patients.

Authors:  F A Rossi; M Ferrero; G E Balladore; L Zecca; F Fraschini; P Ferrario; E Bichisao; G C Monza; V Maresca
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  beta-blocker plasma concentrations and inflammatory disease: clinical implications.

Authors:  R E Schneider; H Bishop
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

6.  Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart.

Authors:  Saeed Sattari; William F Dryden; Lise A Eliot; Fakhreddin Jamali
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

Review 7.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

8.  Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.

Authors:  L O Erikson; E Wåhlin-Boll; I Odar-Cederlöf; L Lindholm; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Selective effect of adjuvant arthritis on the disposition of propranolol enantiomers in rats detected using a stereospecific HPLC assay.

Authors:  M Piquette-Miller; F Jamali
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

Review 10.  Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications.

Authors:  M J Kendall; S R Maxwell; A Sandberg; G Westergren
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.